News | March 20, 2024
AstraZeneca buys biopharmaceutical company Fusion
To accelerate the development of next-generation radioconjugates to treat cancer
To accelerate the development of next-generation radioconjugates to treat cancer
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
Both organisations enter into a long- term collaboration to expand patient access in India
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
More than 10,000 scientific publications containing EUDRAGIT
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Subscribe To Our Newsletter & Stay Updated
